MDVN

Medivation, Inc. News Headlines

$99.4
*  
1.50
1.53%
Get MDVN Alerts
*Delayed - data as of Oct. 23, 2014  -  Find a broker to begin trading MDVN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    MDVN Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Merrimack Pharmaceuticals (MACK) Looks Strong: Stock Up 8.6% - Tale of the Tape
10/24/2014 8:44:00 AM - Zacks.com


Omeros Falls as Enrollment for OMS824 Study is Suspended - Analyst Blog
10/23/2014 4:10:00 PM - Zacks.com


Novartis' Secukinumab Receives Favorable FDA Panel Vote - Analyst Blog
10/23/2014 3:30:00 PM - Zacks.com


First Week of MDVN June 2015 Options Trading
10/23/2014 12:17:35 PM - BNK Invest


Vertex Pharmaceuticals' Kalydeco Wins FDA Panel Backing - Analyst Blog
10/22/2014 5:54:00 PM - Zacks.com


Biogen's Q3 Earnings Top Estimates, View Raised Again - Analyst Blog
10/22/2014 1:10:00 PM - Zacks.com


Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance - Analyst Blog
10/22/2014 11:40:00 AM - Zacks.com


Is Johnson & Johnson's Worst Nightmare Becoming Reality?
10/22/2014 8:39:02 AM - Motley Fool


NewLink-Roche Ink Deal for Oncology Candidate Development - Analyst Blog
10/21/2014 6:05:00 PM - Zacks.com


3 Stocks That Could Surprise This Earnings Season
10/21/2014 3:44:02 PM - Motley Fool


Will Quest Diagnostics (DGX) Surprise Earnings in Q3? - Analyst Blog
10/21/2014 3:30:00 PM - Zacks.com


Will Zimmer (ZMH) Miss Earnings Estimates this Quarter? - Analyst Blog
10/21/2014 3:10:00 PM - Zacks.com


3 Drugs Critical to Johnson & Johnson's Future
10/21/2014 8:26:02 AM - Motley Fool


Will Boston Scientific (BSX) Surprise this Earnings Season? - Analyst Blog
10/20/2014 3:20:00 PM - Zacks.com


Infinity Pharmaceuticals' Duvelisib Fails in Mid-Stage Study - Analyst Blog
10/17/2014 5:00:00 PM - Zacks.com


Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog
10/17/2014 4:30:00 PM - Zacks.com


Intra-Cellular Therapies Reveals Top-line Data on ITI-007 - Analyst Blog
10/16/2014 5:50:00 PM - Zacks.com


Tekmira Presents Data on Hepatitis B Candidate TKM-HBV - Analyst Blog
10/16/2014 5:30:00 PM - Zacks.com


Alexion (ALXN) Seeks Japanese Approval for Asfotase Alfa - Analyst Blog
10/16/2014 4:30:00 PM - Zacks.com


Agios (AGIO) Rises on Expansion of Phase I Study on AG-221 - Analyst Blog
10/16/2014 4:10:00 PM - Zacks.com


Can Illumina (ILMN) Keep the Earnings Streak Alive in Q3? - Analyst Blog
10/16/2014 1:50:00 PM - Zacks.com


Orexigen Up on $100M Milestone Payment from Takeda - Analyst Blog
10/16/2014 1:37:00 PM - Zacks.com


Shire (SHPG) Shares Crash on Concerns Over AbbVie Buyout - Analyst Blog
10/16/2014 12:47:00 PM - Zacks.com


MannKind (MNKD) Worth Watching: Stock Gains 12.9% - Tale of the Tape
10/16/2014 9:46:00 AM - Zacks.com


Should Genomic Health (GHDX) Be in Your Portfolio Now? - Analyst Blog
10/15/2014 6:52:00 PM - Zacks.com